Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Infliximab Clear all
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 1, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 1, 2026, 8:59 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

NCT02624037
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Individualized Dosage Precision IFX Dashboard
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 45 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 1, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients

NCT02434133
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Blood Draw/Data Collection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 1, 2026, 8:59 AM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

NCT00959725
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2009 · Synced Sep 1, 2026, 8:59 AM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 1, 2026, 8:59 AM EDT
Terminated No phase listed Observational

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

NCT01759017
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 1, 2026, 8:59 AM EDT
Recruiting No phase listed Observational

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

NCT04372108
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Ustekinumab, Other Biologic Therapies
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 1, 2026, 8:59 AM EDT
Withdrawn Phase 2 Interventional

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

NCT02763761
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 1, 2026, 8:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

NCT00958906
View directory record Official record
Conditions
Uveitic Macular Edema, Intraocular Inflammation
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 1, 2026, 8:59 AM EDT
Completed No phase listed Observational

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

NCT00819663
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

NCT00228839
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Infliximab
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 1, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Results available

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

NCT01485055
View directory record Official record
Conditions
Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
Interventions
Infliximab and Basiliximab
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Months to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 1, 2026, 8:59 AM EDT
Not yet recruiting Not applicable Interventional

Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study

NCT07257068
View directory record Official record
Conditions
Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
Interventions
Infliximab
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

NCT00791557
View directory record Official record
Conditions
Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

NCT04505410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
Other · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

NCT00589628
View directory record Official record
Conditions
Chronic Uveitis
Interventions
infliximab
Drug
Lead sponsor
Egla C. Rabinovich
Other
Eligibility
4 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

NCT00948610
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Remicade
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 1, 2026, 8:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab, Infliximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
strength training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Sep 1, 2026, 8:59 AM EDT